top of page

Something to Salivate Over

  • Writer: Patrick Chung
    Patrick Chung
  • Apr 29, 2021
  • 1 min read

Originally published at NEA.com


About five years ago, I was paid the most arresting visit. A first-time entrepreneur named Anne Wojcicki came to NEA with an amazing idea, on a single sheet of paper: she wanted to make gene sequencing technology accessible to regular consumers for the first time ever, enabling all of us to learn amazing things about ourselves; to potentially live healthier, longer lives; and to completely revolutionize medical research.


And all she needed was a little spit.


Today the personal genomics company Anne founded — 23andMe, named for the 23 pairs of chromosomes that make up each person’s genome—is reducing its price to $99, a full order of magnitude from its first price point ($999) in 2007. The company is doing this to genotype one million individuals, and this ambitious goal is being fueled by over $50m in new capital led by DST’s Yuri Milner, along with NEA and existing investors Google and MPM Capital.


 
 
 

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.

© 2023 PatrickChung.org

bottom of page